RGS RGS Healthcare Solutions

Competitor Mapping

Competitor portfolios mapped and compared

RGS combines authorisations, pending filings, tender awards and supply relationships into one view of each competitor: what they hold, where they are expanding, what they are developing, who makes it for them and where they win. Changes are flagged as they happen.

How it works

How Competitor Mapping works

01 · Combine

Combine

Authorisations, pending applications, tender awards and manufacturing links joined at company-group level.

02 · Compare

Compare

Portfolios compared molecule by molecule and market by market against yours.

03 · Watch

Watch

New holdings, filings, wins and supplier changes flagged as they appear.

Competitor Mapping

One view of each competitor, from four kinds of evidence

Portfolio, pipeline, tender record and supply partners on one page per company, kept current.

  • Portfolio overlap with yours
  • Pipeline by molecule and market
  • Tender wins and prices by market

Competitor Mapping

From a map to a decision

Choose markets, plan launches around known entrants, screen partners or brief the board.

  • White space by molecule and market
  • Partner and licensing screening
  • Board-ready competitor briefs

Questions

Questions about Competitor Mapping

How many generic competitors are there per molecule and country?

RGS counts the holders with a valid authorisation, those with a pending application and those that actually bid in tenders, per molecule and country. The three numbers often differ, and the gap shows who is ready to enter.

What does competitor mapping in pharma include?

At RGS it combines four kinds of evidence: marketing authorisations, pending applications, tender awards and manufacturing links. Together they show what each competitor holds, what it is developing, where it wins and who supplies it.

See competitor mapping on your own molecules

Send us your portfolio and markets. We will show you what the data says before the call.